Hodgkin lymphoma: A review and update on recent progress.
Hodgkin lymphoma: A review and update on recent progress.
复制标题
DOI：
10.3322/caac.21438
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Ambinder RF
中科院分区：
文献类型：
--
作者：
Shanbhag S;Ambinder RF
霍奇金淋巴瘤（HL）是一种独特的造血系统肿瘤，其特征是炎症背景下的癌性里德-斯滕伯格细胞。患者通常在 20 岁至 30 岁之间被诊断出来，表现为膈上淋巴结肿大，通常伴有全身 B 症状。即使在晚期疾病中，HL 通过联合化疗、放疗或综合治疗也能高度治愈。尽管相同的 ABVD 化疗方案在过去 30 年来一直是治疗的支柱，但风险适应方法有助于降低低风险患者的治疗，同时加强对高风险患者的治疗。即使初始治疗未治愈的患者也通常可以通过替代化疗组合、新型抗体药物结合物 Brentuximab、高剂量自体或同种异体造血干细胞移植 (allo-HCT) 来挽救。程序性死亡 1 (PD-1) 抑制剂 Nivolumab 和 Pembrolizumab 均在复发/难治性 HL 中表现出高缓解率和持久缓解。替代供体来源和降低强度调节使异基因 HCT 成为更多 HL 患者的可行选择。未来的研究将寻求将新策略整合到早期治疗中，以提高 HL 治愈率并最大限度地减少长期治疗毒性。
Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed when in their 20s-30s, present with supra-diaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced stage disease, HL is highly curable with combination chemotherapy, radiation or combined modality treatment. Although the same ABVD chemotherapeutic regimen has been the mainstay of therapy for over last 30 years, risk adapted approaches have helped de-escalate therapy in low risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate Brentuximab, high dose autologous or allogeneic hematopoietic stem cell transplant (allo-HCT). The Programmed death-1 (PD-1) inhibitors Nivolumab and Pembrolizumab have both demonstrated high response rates and durable remissions in relapse/refractory HL. Alternate donor sources and reduced intensity conditioning have made allo-HCT a viable option for more HL patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long term treatment toxicities.
登录
查看更多内容
影响因子：
45.3
作者：
Diehl, V;Sextro, M;Stein, H
通讯作者：
Stein, H
影响因子：
45.3
作者：
Al-Mansour, Mubarak;Connors, Joseph M.;Savage, Kerry J.
通讯作者：
Savage, Kerry J.
影响因子：
45.3
作者：
Eichenauer, Dennis A.;Pluetschow, Annette;Engert, Andreas
通讯作者：
Engert, Andreas
影响因子：
45.3
作者：
El-Galaly, Tarec Christoffer;d'Amore, Francesco;Hutchings, Martin
通讯作者：
Hutchings, Martin
影响因子：
20.3
作者：
Chen, Robert;Gopal, Ajay K.;Younes, Anas
通讯作者：
Younes, Anas